Kailera Therapeutics, Inc. (NASDAQ: KLRA) is a Healthcare company (Biotechnology) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Kailera Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $12.20, Kailera Therapeutics, Inc. trades at 1.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -102.3%, return on invested capital of -36.4% and a free cash flow yield of -20.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 21.84. Over the past 52 weeks the share price ranged from $9.76 to $28.23, with a beta of 0.50.
Kailera Therapeutics, Inc. does not currently pay a dividend.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Kailera Therapeutics, Inc. (KLRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 71.7% / 30% · Interest income / Revenue 1061100000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 62.3% / 33% · Receivables / Mkt Cap (36m) 0.43% / 49% · Interest income / Revenue 1061100000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 62.3% / 33.33% · Receivables / Mkt Cap (24m) 0.43% / 33.33% · Interest income / Revenue 1061100000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.03% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 79.9% / 33.33% · Receivables / Avg Assets (4Q) 0.51% / 33.33% · Interest income / Revenue 1061100000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 83.3% / 33.33% · (Cash+Recv) / Total Assets 83.9% / 33.33% · Interest income / Revenue 1061100000.0% / 5% | Fail |
No. As of September 2026, Kailera Therapeutics, Inc. (KLRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Kailera Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 1061100000.0% of each dividend: Kailera Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.